Raptor Pharmaceutical (RPTP) Receives FDA Approval for Procysbi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wedbush Downgrades Raptor Pharmaceuticals (RPTP) to Neutral
May 2, 2013 7:33 AM EDTWedbush downgraded Raptor Pharmaceuticals (NASDAQ: RPTP) from Outperform to Neutral with a price target of $7.00 (from $10.00).
Analyst Gregory R. Wade said "We expect a decision from the FDAs Office of Orphan Drugs on PROCYSBIs potential orphan drug exclusivity... More
